Keen Dental: 2025 Revenue of 350 Million Yuan Down 16.59% YoY, Net Profit Up 16.40% YoY
On April 22, 2025, Dezhou Keen Dental Hospital Co., Ltd. released its 2025 annual report, with operating revenue of 350 million yuan, a year-on-year decrease of 16.59%; net profit attributable to shareholders of the parent company was 6.6555 million yuan, a year-on-year increase of 25.41%; overall net profit was 7.6889 million yuan, a year-on-year increase of 16.40%. Against the backdrop of declining revenue, the company achieved profit growth by reducing selling expenses by 28.69% and administrative expenses by 19.21%. By product category, revenue from oral implantology projects was 122 million yuan, down 25.86% year-on-year; restorative projects revenue was 79 million yuan, down 13.11% year-on-year; pediatric dentistry and orthodontic projects revenue was 47 million yuan, down 18.33% year-on-year; oral periodontal projects revenue was 42 million yuan, down 0.06% year-on-year. As of the end of 2025, the company had 14 medical institutions, with a total operating area exceeding 28,000 square meters and 310 dental chairs.
Jibo Medical 2025 Annual Report: Net Profit Attributable to Parent Company Up 47%, Orthodontic Business Up 24% YoY
On April 24, 2026, Guangdong Jibo Medical Group Co., Ltd. released its 2025 annual report. The report showed that the company achieved operating revenue of 370 million yuan, a year-on-year increase of 3.90%; net profit attributable to shareholders of the listed company was 34.1269 million yuan, a year-on-year increase of 47.14%; gross margin increased from 30.12% to 34.23%. Revenue from dental implantation services was 148 million yuan, with gross margin rising to 36.12%; orthodontic treatment business achieved revenue of 48.3075 million yuan, a year-on-year increase of 24.09%, with gross margin rising to 30.14%. As of the end of 2025, the company had established 32 oral medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area, employing nearly 250 licensed physicians and a total of 1,145 staff.
Modern Dental Group Limited 2025 Annual Report: Revenue of 3.737 Billion HKD, Net Profit Up 47.7% YoY
On March 26, 2026, Modern Dental Group Limited released its 2025 performance report, with revenue of 3.737 billion HKD, a year-on-year increase of 11.1%; net profit of 601 million HKD, a year-on-year increase of 47.7%. Digital solution cases reached 1.0392 million, an increase of 32.7%. Revenue from fixed prosthetics was 2.205 billion HKD, accounting for 63.0% of total revenue. The European market performed strongly, with revenue of 1.887 billion HKD, representing 50.5% of total revenue. North America and Greater China saw declines of 7.4% and 7.1%, respectively. In 2025, Modern Dental Group Limited acquired Thailand's Hexa Ceram to enhance its capabilities in the Southeast Asian market. The company will continue to increase investment in digital R&D and mergers and acquisitions.
Yingguan Dental 2025 Annual Report: 3D Printing Reduces Operating Costs, Gross Margin Rises to 45.2%
On April 24, 2026, Beijing Yingguan Dental Technology Co., Ltd. released its 2025 annual report. The report showed that the company achieved operating revenue of 40.0002 million yuan, a year-on-year decrease of 0.06%; net profit attributable to shareholders was 8.656 million yuan, a year-on-year increase of 16.23%. Gross margin reached 45.23%, an increase of 2.68 percentage points from the previous year, mainly due to the application of 3D printing technology, which reduced operating costs by 4.73%. Although the Beijing market contributed 95.47% of revenue, revenue from non-Beijing regions decreased by 46.51% year-on-year. As of press time, the company has not disclosed how it plans to address the risk of business regional concentration.
Perfect 2025 Annual Report: Net Profit Attributable to Parent Company Turns Profitable, Toothpaste Sales Up 183.31% YoY
On April 24, 2026, Perfect Group disclosed its 2025 annual report. The report showed that the company's net profit attributable to shareholders of the parent company was 115 million yuan, turning profitable compared to a loss of 77 million yuan in 2024. Operating revenue for 2025 was 1.535 billion yuan, a year-on-year increase of 18.20%; net cash flow from operating activities reached 213 million yuan, a year-on-year increase of 53.50%. Revenue from oral cleaning and care business was 1.037 billion yuan, a year-on-year increase of 23.00%. Toothpaste sales reached 89.074 million units, a year-on-year increase of 183.31%. As of the end of 2025, the company held a total of 29 invention patents, 129 utility model patents, and 198 design patents. The company plans to distribute a cash dividend of 0.27 yuan per share (including tax) to all shareholders, with a total cash dividend payout of 35.157 million yuan, accounting for 30.63% of net profit attributable to the parent company.
Sinocera 2025 Annual Report: Revenue of 4.583 Billion Yuan, Biomedical Materials Segment Revenue Up 2.11% YoY
On April 21, 2026, Shandong Sinocera Functional Material Co., Ltd. disclosed its 2025 annual report. The report showed that the company achieved annual operating revenue of 4.583 billion yuan, a year-on-year increase of 13.24%; net profit attributable to shareholders of the listed company was 610 million yuan, a year-on-year increase of 0.91%. Among this, the biomedical materials segment achieved revenue of 930 million yuan, a year-on-year increase of 2.11%, with growth rates lower than the group's overall level. The gross margin for this segment was 51.21%, a decrease of 5.46 percentage points compared to the same period last year. The company stated it will continue to deepen its presence in the European and American markets and plans to acquire Australian listed oral consumables supplier SDI to expand its international business.
Lepu Medical 2025 Annual Report: Revenue of 6.483 Billion Yuan, Net Profit Attributable to Parent Company Up 290% YoY
On April 23, 2026, Lepu Medical released its 2025 annual report, achieving operating revenue of 6.483 billion yuan, a year-on-year increase of 6.22%; net profit attributable to shareholders of the listed company was 962 million yuan, a year-on-year increase of 289.57%. Net cash flow from operating activities was 1.517 billion yuan, a significant year-on-year increase of 106.48%. The company stated that through full supply chain cost control and organizational structure optimization, its core business operations remained stable, providing financial support for strategic transformation. Revenue from the medical devices segment was 3.254 billion yuan, a slight year-on-year decrease of 2.18%; the pharmaceutical segment revenue was 2.165 billion yuan, a year-on-year increase of 23.18%. As of the end of 2025, the company's total assets were 26.139 billion yuan, a year-on-year increase of 6.37%.
Dabo Medical 2025 Annual Report: Dental Products Revenue of 71 Million Yuan, Up 8.04% YoY
In 2025, Dabo Medical achieved operating revenue of 2.601 billion yuan, a year-on-year increase of 21.79%; net profit attributable to the parent company was 600 million yuan, a year-on-year increase of 68.06%. Revenue from dental products was 71 million yuan, a year-on-year increase of 8.04%, but the growth rate slowed significantly from 28.25% in 2024, and its share of total operating revenue decreased from 3.08% to 2.73%. Overseas business achieved revenue of 312 million yuan, a year-on-year increase of 43.81%, with its share of total revenue increasing from 10.16% to 12.00%. As of the end of 2025, the company's total assets were 4.924 billion yuan, a year-on-year increase of 11.43%.
Dencare: 2025 E-commerce Model Revenue of 588 Million Yuan, Up 22.33% YoY
In 2025, Dencare achieved operating revenue of 1.716 billion yuan, a year-on-year increase of 9.98%; net profit attributable to shareholders of the listed company was 181 million yuan, a year-on-year increase of 12.35%. In terms of the e-commerce model, 2025 revenue was 588 million yuan, a year-on-year increase of 22.33%, accounting for 34.26% of total revenue. In the first quarter of 2026, the company achieved operating revenue of 495 million yuan, a year-on-year increase of 15.09%; net profit attributable to shareholders of the listed company was 52 million yuan, a year-on-year increase of 20.01%. The report noted that the improvement in profitability in the first quarter of 2026 was mainly due to a significant narrowing of asset impairment losses, which were only 168,700 yuan, a year-on-year decrease of 96.28%. As of press time, Dencare's retail sales value share in the adult toothpaste and children's toothpaste markets both ranked third in the industry, while its toothbrush market share rose to second in the industry.
Ivoclar Vivadent Builds First Factory in China, Phase One Investment of 10 Million USD for Automated Dental Medical Device Production Line
On April 17, 2026, Ivoclar Vivadent Group signed an agreement with Shanghai Xinzhuang Industrial Zone, announcing a phase one investment of 10 million USD to build an automated dental medical device production line. This marks the group's first production move to mainland China, filling its manufacturing gap in China. The project focuses on the localized production of products such as dental filling materials and adhesives. Minhang District currently has 26 oral medical device manufacturers, including companies like Straumann and 3M. It is expected that the three companies will achieve technological complementarity, promoting the integrated development of high-end dental care. The industrial zone will also provide full-process one-stop services to support enterprise development. As of press time, Ivoclar Vivadent has not disclosed the specific start-up and mass production timeline for the production line.
Haili Biology Expects 2025 Revenue of 188 Million Yuan, Company Stock May Face Delisting Risk Warning
On April 24, 2026, Haili Biology issued its third delisting risk warning announcement, estimating 2025 annual operating revenue at 188 million yuan, with a net loss after deducting non-recurring gains and losses of approximately 620 million yuan, falling below the regulatory standard of 300 million yuan. If the audited data for 2025 triggers relevant rules, the company's stock will be suspended from trading from the date of the annual report disclosure and will be subject to a delisting risk warning within five trading days. Although the unit price of oral bone graft and membrane products increased by 45% quarter-on-quarter, overall performance remains under pressure.
Medical AI Technology Company RIIG Completes Over 6 Million USD Series A Financing for Global Market Expansion
On April 20, 2026, medical AI technology company RIIG Technology completed a Series A financing of over 6 million USD, co-led by family offices, listed entities, and high-net-worth individuals. The financing will be used to accelerate the deployment of its AI-driven medical insurance platform, deepen the technology stack, and expand into global markets. Currently, RIIG Technology's dental solutions have been integrated with mainstream clinic management systems such as OpenDental and Dentrix Cloud, with more integration projects underway. To support multi-domain model R&D, the company is establishing an AI Center of Excellence and has acquired an NVIDIA DGX B300 system. RIIG Technology has established a strategic joint venture partnership with a Dubai government-backed institution and set up a Canadian subsidiary to enhance border security and protect the supply chain.
Dental Medical Technology Company MINISH Secures 22 Million USD in Funding, Valuation Rises to 110 Million USD
On April 23, 2026, dental medical technology company MINISH Technology received a 22 million USD investment from VIG Partners, bringing its valuation to approximately 110 million USD. The transaction gives VIG Partners a 20% minority stake in the company. MINISH Technology stated it will use the funds to accelerate global expansion, with plans for a large-scale entry into the North American market. Founded in 2021 and headquartered in Seoul, South Korea, the company focuses on digital tooth restoration and minimally invasive aesthetic treatments. As of press time, MINISH Technology plans to hold a three-day biomimetic restoration training course in California, USA, from May 8 to 10, 2026, offering 20 hours of continuing education credits.
Investment of Approximately 354 Million RMB, Nanyang Technological University, Singapore Develops Nano Coating for Dental Restorations
On April 20, 2026, Nanyang Technological University, Singapore and nanotechnology solutions company Nanofilm Technologies International announced an investment of 66 million SGD (approximately 354 million RMB) to establish the NTI-NTU Corporate Laboratory, aiming to develop advanced nano-coating technology for dental restorations to improve tissue integration and reduce infection risk. The carbon-based nanocomposite coating developed by the laboratory is made from a mixture of various nanomaterials, enhancing the durability of implants and promoting tissue healing. The global market demand for high-performance coatings is expected to exceed 200 billion USD by 2030. This collaboration will help translate research results into marketable solutions.
Focus Acquires Dental IT Service Company, Marks First Strategic Expansion into Dental Market
On April 20, 2026, medical IT service company Focus completed the acquisition of dental IT service company Progressive Solutions, marking Focus's first strategic entry into the dental market. Progressive Solutions has 25 years of experience in dental technology infrastructure services, and Focus has served over 1,400 clients cumulatively. This acquisition integrates Progressive Solutions' three dental technology brands: Dental Backup, Dental Secure Mail, and MyBridge Communications, providing cybersecurity and technical support to dental clinics. Progressive Solutions will continue to serve existing clients under its original brand in Missouri and Illinois, while operating under the Focus brand in other markets.
US Medical Virtual Assistant MMM Enters Dental Sector, Launches Specialized Training to Reduce Clinic Administrative Burden
On April 17, 2026, US medical virtual assistant provider My Mountain Mover (MMM) announced its official entry into the dental industry, launching virtual assistant services and specialized training programs designed for dental clinic operational workflows. The program covers dental reception, appointment management, billing and insurance processing, as well as hands-on simulation training for mainstream dental clinic management systems, aiming to reduce the administrative burden on clinics. MMM currently has over 1,500 active virtual assistants serving more than 1,000 doctors and plans to continuously evolve based on the needs of modern dental clinics.
2026 Medical Insurance Fund Self-Inspection and Rectification Launched, Oral Field Included in National Key Rectification Scope for the First Time
On April 14, 2026, the National Healthcare Security Administration announced the nationwide launch of the 2026 self-inspection and rectification work for designated medical institutions regarding the illegal use of the Medical Insurance Fund. This action aims to further consolidate the self-management responsibility of designated medical institutions and strengthen the fund's safety防线. The self-inspection and rectification will focus on areas including oral, endocrinology, and psychiatric medicine, targeting violations by oral medical institutions. The work is divided into three phases: the first phase, completed by the end of March, involved list formulation; the second phase requires medical institutions to conduct self-inspections by the end of April; and the third phase will involve random inspections and re-examinations starting in May. The NHSA stated that this work is an important measure to promote regulation.
Northern Ireland Department of Health Invests 8 Million Pounds to Support Dental Services, Plans to Establish Emergency Dental Clinics
Recently, the Northern Ireland Department of Health announced an investment of 8 million pounds (approximately 71.8 million RMB) to support dental services, planning to establish emergency dental clinics in the Western Trust area specifically to provide urgent care for patients unable to secure routine dental appointments. This plan aims to alleviate current practitioner shortages and service pressure, adding 6 new dental foundation training places to increase training capacity and retain newly graduated dentists. Additionally, the 30% fee subsidy for priority treatment will continue. Health Minister Mike Nesbitt emphasized that the plan helps enhance the long-term sustainability of public dental services.
University of Pennsylvania Develops Bioengineered Chewing Gum, Claims to Simultaneously Eliminate Two Oral Cancer-Related Carcinogenic Bacteria
On April 21, 2026, a research team from the University of Pennsylvania School of Dental Medicine published a study showing that a bioengineered legume chewing gum extract can reduce levels of three microorganisms associated with head and neck squamous cell carcinoma. Experimental data showed that the gum reduced HPV levels by 93% in saliva samples and 80% in oral rinse samples. After bioengineering, a single dose reduced levels of Porphyromonas gingivalis and Fusobacterium nucleatum to nearly zero without affecting beneficial oral flora. The research is expected to advance to clinical trials and could potentially serve as an adjunct therapy or preventive measure to existing treatments.
| About DGN:DentalGoodNews (DGN) is a trusted professional media platform dedicated to the global dental industry. We deliver in-depth coverage of corporate news, policy & regulation, investment & funding, and clinical frontiers — serving dental institutions, device manufacturers, investors, and industry researchers worldwide. Contact us: haodeya@dongxizixun.com |
